[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.211.1.15. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 2,000
Citations 0
Review
February 2017

Diversity in Dermatology Clinical TrialsA Systematic Review

Author Affiliations
  • 1Harvard Combined Dermatology Residency Training Program, Harvard Medical School, Boston, Massachusetts
  • 2Brigham & Women’s Hospital, Harvard Medical School, Boston, Massachusetts
  • 3Walgreen Co, Deerfield, Illinois
  • 4Department of Dermatology, Brigham & Women’s Hospital, Harvard Medical School, Boston, Massachusetts
JAMA Dermatol. 2017;153(2):193-198. doi:10.1001/jamadermatol.2016.4129
Key Points

Question  What is the racial, ethnic, and sex makeup of participants in randomized clinical trials of dermatologic conditions?

Findings  In this systematic review of 626 trials conducted in 2010 through 2015, there was a low level of reporting of racial and ethnic composition of trial participants. Those US trials that reported race and ethnicity included a proportional number of women and African Americans compared with the general population, but Hispanic representation was lower than that of the general population of the United States.

Meaning  While dermatologic clinical trials conducted in the United States are racially diverse, the field must increase reporting of race and ethnicity and strive for representative study cohorts especially with respect to ethnic diversity.

Abstract

Importance  Though there have been significant shifts in US demographic data over the past 50 years, research cohorts lack full racial and ethnic representation. There is little data available regarding the diversity of dermatology research cohorts with respect to sex, race, and ethnicity.

Objective  To characterize and assess the representation of racial and ethnic minorities and women in randomized controlled trials across a range of dermatologic conditions.

Evidence Review  All randomized clinical trials (RCTs) were identified between July 2010 and July 2015 within the PubMed database using the following keywords: “psoriasis,” “atopic dermatitis,” “acne,” “vitiligo,” “seborrheic dermatitis,” “alopecia areata,” and “lichen planus.” Diverse study populations were defined as including a greater than 20% racial or ethnic minority participants based on US census data. The distributions of sex and race groups in studies were compared by journal type, disease type, and funding source.

Findings  Of the 626 articles reporting RCTs included in this analysis, 532 (85.0%) reported the sex of study participants. Overall, 52 of 626 international (11.3%) studies and 58 of 97 studies (59.8%) conducted exclusively within the United States reported on the racial or ethnic demographics of study participants. Across all RCTs exclusively recruited within the United States that reported race, 74.4% of study participants were white. Disease type was significantly associated with the degree of racial diversity (P < .001) within a study cohort: 30.0% of US-based psoriasis had more than 20% racially or ethnically diverse research participants as compared with 73.9% of acne studies and 91.7% of eczema studies.

Conclusion and Relevance  Dermatologic clinical trials within the United States reflect the growing diversity of the US population. Reporting of both sex and racial/ethnic diversity of research cohorts is still lacking, especially among studies conducted outside of the United States.

×